Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 9/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.34 |
| ▸ | DLK1 | P80370 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20448501 | 0.85 | IDH1 (0.33) | — | |
| SCHEMBL18436556 | 0.82 | PRKDC (0.45) | MAP3K12PRKDCMTORPIK3CASYK | |
| SCHEMBL25889732 | 0.79 | MAP3K12 (0.39) | MAP3K12PRKDCMTORPIK3CASYK | |
| SCHEMBL25889731 | 0.79 | MAP3K12 (0.39) | MAP3K12PRKDCMTORPIK3CASYK | |
| SCHEMBL15399356 | 0.79 | MAP3K12 (0.44) | MAP3K12PRKDCMTORPIK3CAMAP3K13 | |
| SCHEMBL12082429 | 0.79 | SOS1 (0.39) | MAP3K12PRKDCMTORPIK3CASOS1 | |
| SCHEMBL19221692 | 0.73 | MAPT (0.41) | PRKDC | |
| SCHEMBL23107400 | 0.73 | CHRNB2 (0.55) | MAP3K12MTORPIK3CAMAP3K13SOS1 | |
| SCHEMBL12697201 | 0.73 | CHRNB2 (0.55) | MAP3K12MTORPIK3CAMAP3K13SOS1 | |
| SCHEMBL23387212 | 0.71 | NSD2 (0.42) | PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180265467-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | SELVITA S.A. (PL) | 2018-09-20 | — | — | US | claimed |
| US-20180265467-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | SELVITA S.A. (PL) | 2018-09-20 | — | — | US | disclosed |
| EP-3356331-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | Selvita S.A. (PL) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265467-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | LDHB, LDHA, PDK1 | MAP3K12 1787/4885PRKDC 847/4885MTOR 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.